welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
- log in
Brain Involvement in Dystrophinopathies (WP5) Part 1
study id #: NCT04583917
condition: Duchenne Muscular Dystrophy, Becker Muscular Dystrophy
status: not yet recruitingpurpose:
The objective of this study is to collect data from a large cohort of individuals with DMD and BMD focusing on the neurobehavioural aspects of these conditions and their correlation to the location of the DMD gene mutation.
mechanism of action: No pharmaceutical intervention
last updated: October 22, 2020
start date: November 2020
estimated completion: October 2022
phase of development: N/A
size / enrollment: 800
Intellectual disability and neurobehavioural comorbidities affect at least 50% of the individuals with Duchenne muscular dystrophy (DMD), which, although a rare genetic disease, is the most common form of muscular dystrophy in childhood. Several studies have documented that 25% of the DMD population has intellectual disability with recent studies suggesting that autism and clinically relevant hyperactivity affects 20% and 25% of DMD boys respectively. A milder allelic variant, named Becker muscular dystrophy (BMD), has similar prevalence in the population and is also associated with variable degrees of central nervous system (CNS) comorbidities, which however have been less well defined.
We will address these deficiencies in a large multicentre study funded by the European Commission (EU H2020) involving 6 countries (Denmark; The Netherlands; France; Spain; Italy and UK) with the largest European neuromuscular centres and advocacy groups. The aim will be to study the neurobehavioural aspects of DMD and BMD as well as their correlation to the genotype. This study will involve male participants with DMD aged 5-17 years and with BMD aged 5-50 years. It will comprise of online questionnaires that will be completed either by a parent of a participant <17 years or an adult participant. The questionnaires take approximately 90 minutes to complete, however this can be done in multiple sittings. Currently there is a lack of information to assist the prognosis of CNS comorbidities, as existing databases and registries typically focus on the motor milestones and physical disability of these patients. There is therefore, an urgent need to present the course and outcomes in DMD and BMD patients with a wide range of DMD mutations, to provide information at the point of diagnosis and onwards for families, clinicians and service providers. It will also assist in paving the way to greater biological understanding and personalization of interventions.
- CNS Comorbidity Pheotyping [ Time Frame: 90 minutes ]
Correlate CNS comorbidity phenotypes with genotype in DMD and BMD patients
• Eligible Sexes: male
• genetically-proven diagnosis of DMD
• genetic mutation that abrogates expression of Dp427 alone (assigned in DMD Group 1: Dp427-/Dp140+) or both Dp427 and Dp140 (assigned to DMD Group 2: Dp427-/Dp140-); or all isoforms (assigned to DMD group 3)
For BMD patients:
• age 5-50 years
• genetically-proven diagnosis of BMD
• genetic mutation that decreases expression of Dp427 alone (assigned to BMD Group 1), of both Dp427 and Dp140 (assigned to BMD Group 2), or of all the isoforms (assigned to BMD group 3).
• Lack of a molecular diagnosis of DMD or BMD
• Mutation falls outside the regions of interest
• A severe co-morbidity or planned surgical intervention within 6 months from the study which could interfere with the well-being of the participant
The influence of visual and tactile perception on hand control in children with Duchenne muscular dystrophyAim: To investigate tactile perception ...
Motor and cognitive delay in Duchenne muscular dystrophy: implication for early diagnosisObjectives: To examine the relationship...
Neurodevelopmental Needs in Young Boys with Duchenne Muscular Dystrophy (DMD): Observations from the Cooperative Int...Introduction: Duchenne muscular dystroph...
Duchenne Muscular Dystrophy & the Brainhttps://www.youtube.com/watch?v=70pEF4H3...
Juliane Florence, PhDDr. Florence is the Director of clinical...
Feasibility of Virtual Reality in Children With Neuromuscular Disease, Effectiveness of Virtual Reality and Biofeedb...Our study is a randomized controlled stu...
Neurology care, diagnostics, and emerging therapies of the patient with Duchenne muscular dystrophyDuchenne muscular dystrophy is the most ...